Clinical Trials Browser

Phase 2 × Bulbo-Spinal Atrophy, X-Linked × darolutamide × Clear all

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked